Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 3/20 | 0.55 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.55 |
| ▸ | PGR | P06401 | 2/20 | 0.49 |
| ▸ | CMA1 | P23946 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | KIF11 | P52732 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 2/20 | 0.42 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.42 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.42 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.42 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.42 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9286435 | 0.86 | CMA1 (0.61) | PDE3BPDE3APGRCMA1ALDH1A1 | |
| SCHEMBL9832347 | 0.77 | CMA1 (0.50) | PDE3BPDE3APGRCMA1ALDH1A1 | |
| SCHEMBL7332557 | 0.76 | HTR1A (0.51) | PDE3BPDE3APGRCMA1 | |
| SCHEMBL16700823 | 0.75 | ALDH1A1 (0.60) | ALDH1A1 | |
| SCHEMBL20106905 | 0.75 | PDE3B (0.55) | PDE3BPDE3APGRCMA1ALDH1A1 | |
| SCHEMBL489133 | 0.75 | PDE3B (0.55) | PDE3BPDE3APGRCMA1ALDH1A1 | |
| SCHEMBL1848968 | 0.75 | PDE3B (0.55) | PDE3BPDE3APGRCMA1ALDH1A1 | |
| SCHEMBL6190639 | 0.75 | POLB (0.56) | PDE3BPDE3APGRCMA1ALDH1A1 | |
| SCHEMBL435577 | 0.75 | PDE3B (0.59) | PDE3BPDE3APGRCMA1ALDH1A1 | |
| SCHEMBL7709830 | 0.75 | PDE3B (0.55) | PDE3BPDE3APGRCMA1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 180 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118852811-A | Corrosion-resistant overhead cable | 天津市华夏电缆有限公司 | 2024-10-29 | — | — | CN | claimed |
| WO-2009135925-A1 | SUBSTITUTED N-IMIDAZO[2,1-B]THIAZOLE-5-SULFONAMIDE DERIVATIVES AS 5-HT6 LIGANDS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-11-12 | — | — | WO | claimed |
| EP-2116547-A1 | Substituted N-imidazo(2, 1-b) thiazole-5-sulfonamide derivatives as 5-TH6 ligands | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-11-11 | — | — | EP | claimed |
| EP-0039818-A1 | Substituted 2-(3H)-benzothiazolones, processes for their preparation, their utilization in the preparation of medicines and medicines containing them | Dr. Karl Thomae GmbH (DE) | 1981-11-18 | — | — | EP | claimed |
| JP-61140576-A | — | — | None | — | — | JP | disclosed |
| US-12590071-B2 | Hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2026-03-31 | — | — | US | disclosed |
| US-12590066-B2 | Fused-heterocyclyl-carbonohydrazonoyl dicyanide compounds and use thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2026-03-31 | — | — | US | disclosed |
| US-12528797-B2 | Heterocyclic compounds for medical treatment | C4 THERAPEUTICS, INC. | 2026-01-20 | — | — | US | disclosed |
| US-20250230157-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | RAPPORT THERAPEUTICS, INC. | 2025-07-17 | — | — | US | disclosed |
| EP-4558495-A1 | HETEROARYL COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK4 | Bristol-Myers Squibb Company (US) | 2025-05-28 | — | — | EP | disclosed |
| US-12304908-B2 | Azabenzimidazoles and their use as AMPA receptor modulators | RAPPORT THERAPEUTICS, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| CN-113727972-B | Novel hydrazone derivatives having terminal amine groups substituted with aryl or heteroaryl groups and use thereof | 韩国科学技术研究院 | 2024-12-27 | — | — | CN | disclosed |
| US-4904685-A | Antiallergy and antiinflammatory agents | PFIZER INC. (US) | 1990-02-27 | — | — | US | disclosed |
| US-4835166-A | LIPOXYGENASE, CYCLOOXYGENASE INHIBITORS | PFIZER INC. (US) | 1989-05-30 | — | — | US | disclosed |
| EP-0316649-A2 | Water insoluble azo colouring agents, their preparation and use | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-05-24 | — | — | EP | disclosed |
| EP-0249407-A2 | Antiallergy and antiinflammatory agents | Pfizer Corporation (PA) | 1987-12-16 | — | — | EP | disclosed |
| JP-S61140576-A | BENZOTHIAZOLONE DERIVATIVE, PREPARATION THEREOF, AND AGRICULTURAL AND HORTICULTURAL FUNGICIDE CONTAINING SAID DERIVATIVE AS ACTIVE COMPONENT | IDEMITSU KOSAN CO LTD | 1986-06-27 | — | — | JP | disclosed |
| EP-0039818-A1 | Substituted 2-(3H)-benzothiazolones, processes for their preparation, their utilization in the preparation of medicines and medicines containing them | Dr. Karl Thomae GmbH (DE) | 1981-11-18 | — | — | EP | disclosed |
| US-4122117-A | Indandione bis-azomethine pigments | DAINIPPON INK & CHEMICALS, INC. (JP) | 1978-10-24 | — | — | US | disclosed |
| US-4012371-A | Benzinaldazolyl-, quinolonyl-, or phenmorpholonylazo-3-cyano-4-methyl-1,2-[1',2']-benz-[4',5']-imidazolo-6-hydroxypyridine colorants | CIBA-GEIGY CORPORATION (US) | 1977-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12528797-B2 | Heterocyclic compounds for medical treatment | CRBN, CUL2, ADRM1 | PDE3B 4687/4885PDE3A 4616/4885PGR 3367/4885 |
| US-12590071-B2 | Hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof | ABL1, TH, CYP3A43 | PDE3B 491/4885PDE3A 437/4885PGR 2627/4885 |
| US-12590066-B2 | Fused-heterocyclyl-carbonohydrazonoyl dicyanide compounds and use thereof | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR1, CLIC1 | PDE3B 2123/4885PDE3A 2361/4885PGR 3497/4885 |
| US-12304908-B2 | Azabenzimidazoles and their use as AMPA receptor modulators | GRIN1, GRIN2B, GRIN3A | PDE3B 962/4885PDE3A 914/4885PGR 1404/4885 |
| US-20250230157-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | GRIN1, GRIN2B, GRIN3A | PDE3B 939/4885PDE3A 932/4885PGR 1444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.